Here are relevant reports on : fertility-drugs-market
-
Age-related Macular Degeneration (AMD) Drugs Market by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), Molecule (Ranibizumab, Aflibercept, Faricimab), Approval Type (Biologic, Biosimilar), Type of AMD, End User - Global Forecast to 2029
The global age-related macular degeneration (AMD) drugs market, valued at US$9.55 billion in 2023, stood at US$10.46 billion in 2024 and is projected to advance at a resilient CAGR of 10.7% from 2024 to 2029, culminating in a forecasted valuation of US$17.37 billion by the end of the period. Factors such as the increase in the prevalence of AMD cases due to the changing lifestyle and dietary habits such as smoking, alcohol consumption, and lack of physical activity, a growing focus on research and development highlighted by steady development and approvals of AMD drugs along with improvements in reimbursement policies providing better and affordable access to therapeutic AMD drugs, supports the growth of this market.
- Published: September 2024
- Price: $ 4950
- TOC Available:
-
Rotator Cuff Injury Treatment Market by Modality (Surgical (Arthroscopy, Shoulder Replacement, Tendon Repair), Physiotherapy (Braces, Cold Compression), Drug Therapeutics (Anti-inflammatory Drugs, Injections), Orthobiologics) - Global Forecast to 2026
The global rotator cuff injury treatment market growth is primed to transition from $989.3 million in 2021 to $1,244.2 million by 2026, showcasing a strong CAGR of 4.7%. The key factors fueling the growth of this market include an increase in sports-related shoulder injuries, technological advancements in arthroscopic surgical devices, increase in aging population with osteoarthritis, strong focus of players towards launch of highly advanced arthroscopic treatment devices.
- Published: April 2022
- Price: $ 4950
- TOC Available:
-
Infertility Treatment Market Size, Share & Trends by Product (Equipment, Media, Accessories), Procedure (ART (IVF,ICSI, Surrogate), Insemination, Laparoscopy, Hysteroscopy, Patient Type (Female, Male), End User (Fertility Clinics, Hospitals, Research) & Region - Global Forecast to 2026
The size of global infertility treatment market in terms of revenue was estimated to be worth USD 1.5 billion in 2021 and is poised to reach USD 2.2 billion by 2026, growing at a CAGR of 8.1% from 2021 to 2026. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: October 2021
- Price: $ 4950
- TOC Available:
-
Injection Pen Market Size, Share & Trends by Type (Disposable and Reusable Pens), Therapy (Diabetes Therapy (Insulin, GLP-1), Growth Hormone Therapy, Osteoporosis, obesity, fertility), End User (Homecare and Hospitals & Clinics), and Region - Global Forecast to 2030
The global injection pen market, valued at US$43.8 billion in 2023, stood at US$47.0 billion in 2024 and is projected to advance at a resilient CAGR of 7.9% from 2024 to 2030, culminating in a forecasted valuation of US$74.1 billion by the end of the period. The surging cases of chronic diseases globally, the launch and approval of new, advanced products, the growing trend towards smart devices, and favorable developments in government policies to promote low-cost injections will stimulate market growth.
- Published: August 2024
- Price: $ 4950
- TOC Available:
-
Cover Crops Market by Type (Legumes, Grasses, & Broadleaf Non-Legumes), Application (Soil Fertility Management, Soil Erosion Prevention, Weed Management, & Pest Management), Seed (Certified Seed & Farmed Saved Seed) and Region - Global Forecast to 2029
According to MarketsandMarkets, the cover crops market is projected to reach USD XX billion by 2029 from USD XX billion by 2024, at a CAGR of 6.2% during the forecast period in terms of value. Key players in the cover crops market are YIELD10 BIOSCIENCE, INC (US), Advance Cover Crops (US), Johnston Seed Company (US), Cope Seeds & Grain (UK), AGF Seeds Pty. Ltd (Australia), Lidea Seeds (France), Hudson Valley Seed Company (US), Capstone Seeds (South Africa), ProHarvest Seeds (US), Hancock Farm & Seed Co (US), Renovo Seed (US), Swell Seed Company (US), Roundstone (US), Nuseed (Australia), and Victory Seed Company (US).
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Patient Registry Software Market by Disease (Diabetes, Cancer, Rare, Asthma, Kidney), Product (Drugs, Device), Use Case (Population Health, Research), End User [Profit (Pharma, Payer, Hospital), Non-profit (Govt)], and Region - Global Forecast to 2031
The global patient registry software market is projected to reach USD 3.99 billion by 2031 from USD 2.47 billion in 2026, at a CAGR of 10.0% during the forecast period. The prominent players operating in the patient registry software market include IBM (US), IQVIA (US), Health Catalyst (US), Oracle (US), Optum, Inc. (US), Conduent Incorporated (US), Elekta (Sweden), Medidata (Dassault Systèmes) (France), and Dacima Software, Inc. (EvidentIQ) (Germany), among others. These companies adopted strategies such as product launches, product updates, expansions, partnerships, collaborations, and mergers & acquisitions to strengthen their presence in the patient registry software market.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Human Insulin Market By Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Global Forecast to 2020
The global human insulin market size is projected to grow at a CAGR of 8.1%. Market growth can be attributed to factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of this market.
- Published: December 2015
- Price: $ 4950
- TOC Available:
-
Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024
The leukemia therapeutics market is projected to reach USD 17.1 billion by 2024, at a CAGR of 6.8%. Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies. The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.
- Published: May 2019
- Price: $ 4950
- TOC Available:
-
Renal Cancer Drugs Market by therapy (targeted therapy, chemotherapy, and immunotherapy), drug class (anti-angiogenesis, mTOR inhibitors, interleukin, and immune checkpoint inhibitors), indication (renal cell carcinoma, urothelial carcinoma, and others), distribution channel (hospitals, specialty & retail pharmacies and others), and region (North America, Europe, Asia Pacific and Rest of the World (RoW) which includes Latin America and Middle East & Africa) – global forecasts to 2027
The renal cancer drugs market is projected to reach USD 8 billion by 2027 from USD 6 billion in 2022, at a CAGR of 6% during the forecast period.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Grignard Reagents Market by Product Type (Alkyl Grignard Reagents, Vinyl Grignard Reagents, Aryl Grignard Reagents), Application (APIs & Drugs, Agrochemicals, Polymer Synthesis & Functionalization), End-use Industry (Pharmaceutical & Biotechnology, Agriculture, Chemical, Flavors & Fragrances, Research), and Region - Global Forecast to 2030
The grignard reagents market is expected to grow from USD 5.07 billion in 2025 to USD 6.67 billion in 2030, at a CAGR of 5.6% during the forecast period. Prominent companies in this market include Merck KGaA (Germany), Albemarle Corporation (US), WeylChem International GmbH (Germany), HOKKO CHEMICAL INDUSTRY CO., LTD. (Japan), CHEMIUM srl (Belgium), FAR Chemical (US), PMC Group, Inc (US), Boulder Scientific Group (US), Neogen Chemicals Ltd (India), Tokyo Chemical Industry (India) Pvt. Ltd. (India), Optima Chem (US), Shaoxing Shangyu Hualun Chemical Co., Ltd. (China), Nanjing Freehoo Chemical Technology Co., Ltd (China), Chemische Fabrik Karl Bucher GmbH (Germany), and Jiangsu Changjili New Energy Technology Co., Ltd. (China).
- Published: May 2025
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
